| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-59677SS | |||
| Azide and BSA Free | NBP2-80856 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-88113SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB500-181SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-108SS | |||
| Azide and BSA Free | NBP2-80674 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56340SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-90592SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56508SS | |||
| Azide and BSA Free | NBP2-33213 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-60011SS | |||
| Azide and BSA Free | NBP2-81012 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-55376SS | |||
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: Mre11 Antibody (15B8.1E7.6) [NBP2-59677] - Total protein from human HeLa, Jurkat, and mouse MEF and Neuro2A cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-Mre11 in block buffer and detected with an anti-Armenian Hamster HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Mre11-Antibody-15B8-1E7-6-Western-Blot-NBP2-59677-img0001.jpg "Western Blot: Mre11 Antibody (15B8.1E7.6) [NBP2-59677] - Total protein from human HeLa, Jurkat, and mouse MEF and Neuro2A cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-Mre11 in block buffer and detected with an anti-Armenian Hamster HRP secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: Mre11 Antibody (15B8.1E7.6) [NBP2-59677] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-Mre11 (15B8.1E7.6) at 2 ug/ml overnight at 4C and detected with an anti-Armenian hamster IgG Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Mre11-Antibody-15B8-1E7-6-Immunocytochemistry-Immunofluorescence-NBP2-59677-img0003.jpg)
![Immunohistochemistry-Paraffin: Mre11 Antibody (15B8.1E7.6) [NBP2-59677] - IHC analysis of a formalin fixed paraffin embedded (FFPE) tissue section of mouse prostate tissue section using 1:500 dilution of Mre11 antibody (clone 15B8.1E7.6). The signal was developed using HRP-DAB indirect detection method and the sections were counterstained using hematoxylin staining. This Mre11 antibody generated a strong nuclear with mild to moderate cytoplasmic staining in the glandular epithelial cells.](http://images.novusbio.com/fullsize/Mre11-Antibody-15B8-1E7-6-Immunohistochemistry-Paraffin-NBP2-59677-img0005.jpg)
![Flow Cytometry: Mre11 Antibody (15B8.1E7.6) [NBP2-59677] - An intracellular stain was performed on A431 cells with Mre11 [15B8.1E7.6] Antibody NBP2-59677B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/Mre11-Antibody-15B8-1E7-6-Flow-Cytometry-NBP2-59677-img0006.jpg)
![Immunohistochemistry-Paraffin: Mre11 Antibody (15B8.1E7.6) [NBP2-59677] - IHC analysis of a formalin fixed paraffin embedded (FFPE) tissue section of mouse prostate using 1:500 dilution of Mre11 antibody (clone 15B8.1E7.6). The signal was developed using HRP-DAB indirect detection method and the sections were counterstained using hematoxylin staining. This Mre11 antibody generated a strong nuclear positivity with considerable mild to moderate cytoplasmic staining in the glandular epithelial cells. Select cells depicted MRE11 foci which reflects towards the presence of DNA damage in those cells.](http://images.novusbio.com/fullsize/Mre11-Antibody-15B8-1E7-6-Immunohistochemistry-Paraffin-NBP2-59677-img0004.jpg)
![Flow (Intracellular): Mre11 Antibody (15B8.1E7.6) [NBP2-59677] - An intracellular stain was performed on HeLa Cells with Mre11 (15B8.1E7.6) antibody NBP2-59677 (blue). Unstained cells are shown in orange. Cells were fixed with 4% paraformaldehyde, following fixation, cells were permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by armenian hamster IgG Alexa Flour 488-conjugated secondary.](http://images.novusbio.com/fullsize/Mre11-Antibody-15B8-1E7-6-Flow-Intracellular-NBP2-59677-img0002.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Staining of SIAH in human colorectal adenocarcinoma using NB110-88113. Staining of SIAH was not observed in normal colon epithelium. Photos courtesy of Dr. Amy Tang, Mayo Clinic Cancer Center.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0004.jpg "Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Staining of SIAH in human colorectal adenocarcinoma using NB110-88113. Staining of SIAH was not observed in normal colon epithelium. Photos courtesy of Dr. Amy Tang, Mayo Clinic Cancer Center.")
![Immunocytochemistry/Immunofluorescence: SIAH2 Antibody (24E6H3) [NB110-88113] - Staining of SIAH in ovarian carcinoma (OVCR3) cells using NB110-88113.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunocytochemistry-Immunofluorescence-NB110-88113-img0003.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Strong SIAH2 staining in all nuclei in this basal-like breast carcinoma. Image collected and cropped by CiteAb from the following publication (breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2828), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0006.jpg)
![Flow (Intracellular): SIAH2 Antibody (24E6H3) [NB110-88113] - Human HepG2 cell line was stained with Mouse Anti- SIAH2 Monoclonal Antibody (Catalog# NB110-88113, orange), or Mouse IgG1 isotype control (Catalog# MAB002, blue) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog# FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog# FC005).](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Flow-Intracellular-NB110-88113-img0005.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Moderate to strong staining of SIAH2 in the nucleus of a small proportion of the cell in a high nuclear grade ductal carcinoma in situ with comedo necrosis. Image collected and cropped by CiteAb from the following publication (breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2828), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0008.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Occasional weak to moderate SIAH2 (arrows) staining in a luminal type ductal carcinoma. Image collected and cropped by CiteAb from the following publication (breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2828), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SIAH2-Antibody-24E6H3-Immunohistochemistry-NB110-88113-img0007.jpg)
![Immunohistochemistry: SIAH2 Antibody (24E6H3) [NB110-88113] - Immunohistochemistry of candidate biomarkers in prostate cancer. Representative immunohistochemical staining of ACPP, ADAM9, ALDH1A2, CASR, CCND1, CCPG1, CD34, CD44, CD44v6, CHGA, CHMP1A, EI24, ENO2, GADD45B, HA, HAS2, HES6, HMMR, HOXC6, HYAL1, IGF1, IQCK, MAP4K4, MKI67, PAGE4, PLIN2, PTEN, SIAH2, SMAD4, SOX9, SPP1, SYP, & TP53 from prostate cancer tissue microarrays. Scale bar represents 50 μm. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-244), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-88113_mouse-monoclonal-siah2-antibody-24e6h3-310202415175276.jpg)
![Western Blot: Eg5 Antibody [NB500-181] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY KIF11 cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-Eg5.](http://images.novusbio.com/fullsize/Eg5-Antibody-Western-Blot-NB500-181-img0005.jpg "Western Blot: Eg5 Antibody [NB500-181] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY KIF11 cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-Eg5.")
![Immunocytochemistry/Immunofluorescence: Eg5 Antibody [NB500-181] - Staining of HeLa cells fixed in 3.5% paraformaldehyde. Cytoplasmic staining during interphase and spindle staining during mitosis.](http://images.novusbio.com/fullsize/Eg5-Antibody-Immunocytochemistry-Immunofluorescence-NB500-181-img0003.jpg)
![Western Blot: Eg5 Antibody [NB500-181] - Human Eg5 rescues depletion of the Drosophila kinesin-5 family member Klp61F. Western blot analysis of cell lysates prepared from induced and uninduced; control and Klp61F RNAi-treated cells blotted with anti-Eg5 to monitor induction of Eg5-mCherry, anti-Klp61F to confirm depletion of the motor and anti-alpha-tubulin as a loading control. Cells depleted of Klp61F and with Eg5-mCherry induced are referred to as RepEg5 cells. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fonc.2013.00187/abstract), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Eg5-Antibody-Western-Blot-NB500-181-img0006.jpg)
![Immunocytochemistry/ Immunofluorescence: Eg5 Antibody [NB500-181] - Spontaneous assembly of rosettes in iChM5 derivatives.Feeder free cultures iChM5Ap15 & iChM5Bp28 cells in chamber slides were immunostained as indicated. Left panel, emerging rosettes among self-renewing iPSCs; grayscale inset shows 1x magnification of immunostaining of Oct4 alone. Middle panel shows Nanog staining alone with inset at 2X magnification showing presumptive centrosomes (arrows). Bottom left panel shows forming rosettes immunopositive for Sox2 & Eg5. Bottom right panel shows low magnification image of immunostaining of Sox2 in this iChM5Ap15 culture, showing that virtually all cells were immunopositive. Grey scale inset shows representative forming rosette. Asterisks (*) in each panel indicates example of forming rosette. Scale bar, 50 microns. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25426336), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-181_rabbit-polyclonal-eg5-antibody-310202416171491.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers and in high SVCT-2 expression cell lines. Western blot analysis of c-Myc and cyclin D1 in Sw620 and Sw480 cell lines after co-treatment with L-ascorbic acid and phloretin. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0011.jpg "Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers and in high SVCT-2 expression cell lines. Western blot analysis of c-Myc and cyclin D1 in Sw620 and Sw480 cell lines after co-treatment with L-ascorbic acid and phloretin. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: c-Myc Antibody (9E11) [NB200-108] - c-Myc was detected in immersion fixed paraffin-embedded sections of human breast cancer using anti-human mouse monoclonal antibody (Catalog # NB200-108, clone 9E11) at 1:600 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue).Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Immunohistochemistry-Paraffin-NB200-108-img0007.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U937 cells with c-Myc [9E11] Antibody NB200-108AF594 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0014.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Whole cell protein from PC3 (lane 1), U-2 OS (lane 2) and mouse testis (lane 3) was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-c-Myc in 1% milk, and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0006.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers in low SVCT-2 expressing cell lines. Expression of c-Myc and cyclin D1 was analyzed by western blotting in HCT15 and DLD-1 cell lines after L-ascorbic acid treatment. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0012.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Expression of cancer proliferation markers and in high SVCT-2 expression cell lines. Western blot analysis of c-Myc and cyclin D1 in Sw620 and Sw480 cell lines after co-treatment with L-ascorbic acid and phloretin. beta-actin was used as a loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-29386-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0013.jpg)
![Flow (Intracellular): c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E11) NB200-108AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Intracellular-NB200-108-img0008.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E11) NB200-108PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerthrin.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0009.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody [9E11] NB200-108 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0010.jpg)
![Western Blot: HDAC1 Antibody [NB100-56340] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and HDAC1 knockout (KO) HeLa cell line. PVDF membrane was probed with 2.0 ug/ml of Rabbit Anti-Human HDAC1 Polyclonal Antibody (Catalog # NB100-56340) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for HDAC1 at approximately 65 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/HDAC1-Antibody-Knockout-Validated-NB100-56340-img0007.jpg "<b>Genetic Strategies Validation. </b>Western Blot: HDAC1 Antibody [NB100-56340] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and HDAC1 knockout (KO) HeLa cell line. PVDF membrane was probed with 2.0 ug/ml of Rabbit Anti-Human HDAC1 Polyclonal Antibody (Catalog # NB100-56340) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for HDAC1 at approximately 65 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Western Blot: HDAC1 Antibody [NB100-56340] - Analysis of HDAC1 in HEK293 cell lysate with this antibody.](http://images.novusbio.com/fullsize/HDAC1-Antibody-Western-Blot-NB100-56340-img0002.jpg)
![Immunohistochemistry-Paraffin: HDAC1 Antibody [NB100-56340] - Human testis using HDAC1 antibody at 1:250 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/HDAC1-Antibody-Immunohistochemistry-Paraffin-NB100-56340-img0005.jpg)
![Simple Western: HDAC1 Antibody [NB100-56340] - Simple Western lane view shows a specific band for HDAC1 in 0.5 mg/ml of HEK293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HDAC1-Antibody-Simple-Western-NB100-56340-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: Bromodeoxyuridine/BrdU Antibody [NB500-235] - IF analysis of BrdU in Proteinase K pretreated mouse lacrimal gland. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/Bromodeoxyuridine-BrdU-Antibody-Immunocytochemistry-Immunofluorescence-NB500-235-img0006.jpg "Immunocytochemistry/Immunofluorescence: Bromodeoxyuridine/BrdU Antibody [NB500-235] - IF analysis of BrdU in Proteinase K pretreated mouse lacrimal gland. Image courtesy of anonymous customer review.")
![Immunoprecipitation: Bromodeoxyuridine/BrdU Antibody [NB500-235] - Lysate was immunoprecipitated with anti-brdu antibody (NB500-235), 5-methyl cytosine (5-Me), or a no antibody control (No A). An ELISA was then performed to measure total activity.](http://images.novusbio.com/fullsize/Bromodeoxyuridine-BrdU-Antibody-Immunoprecipitation-NB500-235-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB110-90592 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunocytochemistry-Immunofluorescence-NB110-90592-img0008.jpg "Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB110-90592 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB110-89717 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunocytochemistry-Immunofluorescence-NB110-90592-img0009.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody [NB110-90592] - Deregulated MYC transforms breast acini into invasive breast carcinoma in vivo. Tumours harvested in Figure 1C were stained (above) for Ki67/MKI67 and TUNEL and were quantified (below) for the degree of Ki67/MKI67 and TUNEL staining. Individual quantifications per tumour are shown; *P<=0.05, ***P<=0.001, one-way ANOVA with Bonferroni post-test for multiple testing. Scale bar: 100 um. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.038083), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunohistochemistry-NB110-90592-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NB110-90592] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-Ki-67/MKI67 (NB110-90592) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Chromatin-Immunoprecipitation-NB110-90592-img0003.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody [NB110-90592] - Detection of human lymph node. (20X)](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunohistochemistry-NB110-90592-img0004.jpg)
![Immunohistochemistry: Ki67/MKI67 Antibody [NB110-90592] - Detection of human lymph node. (40X)](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunohistochemistry-NB110-90592-img0005.jpg)
![Western Blot: RANK/TNFRSF11A Antibody (9A725) [NB100-56508] - Analysis of RANK in transfected 293 cells using RANK antibody at 2 ug/ml.](http://images.novusbio.com/fullsize/RANK-TNFRSF11A-Antibody-9A725-Western-Blot-NB100-56508-img0003.jpg "Western Blot: RANK/TNFRSF11A Antibody (9A725) [NB100-56508] - Analysis of RANK in transfected 293 cells using RANK antibody at 2 ug/ml."){kind=icon}
![Flow Cytometry: RANK/TNFRSF11A Antibody (9A725) - BSA Free [NB100-56508] - An intracellular stain was performed on Raw264.7 cells with RANK/TNFRSF11A Antibody (9A725) NB100-56508 (blue) and a matched isotype control MAB002 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/RANK-TNFRSF11A-Antibody-9A725-BSA-Free-Flow-Cytometry-NB100-56508-img0012.jpg){kind=icon}
![Flow Cytometry: RANK/TNFRSF11A Antibody (9A725) [NB100-56508] - Intracellular flow cytometry analysis of RANK in 10^6 RAW cells using 2 ug of RANK antibody. Shaded histogram represents RAW cells without antibody; green represents isotype control; antibody red represents RANK antibody.](http://images.novusbio.com/fullsize/RANK-TNFRSF11A-Antibody-9A725-Flow-Cytometry-NB100-56508-img0005.jpg){kind=icon}
![Flow Cytometry: RANK/TNFRSF11A Antibody (9A725) [NB100-56508] - Using the PE direct conjugate An intracellular stain was performed on K-562 cells with RANK/TNFRSF11A (9A725) antibody NB100-56029 (blue) and a matched isotype control NBP1-97005PE (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/RANK-TNFRSF11A-Antibody-9A725-Flow-Cytometry-NB100-56508-img0009.jpg){kind=icon}
![Flow Cytometry: RANK/TNFRSF11A Antibody (9A725) [NB100-56508] - An intracellular stain was performed on Raw264.7 cells with RANK/TNFRSF11A [9A725] Antibody NB100-56508AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/RANK-TNFRSF11A-Antibody-9A725-Flow-Cytometry-NB100-56508-img0010.jpg){kind=icon}
![Flow Cytometry: RANK/TNFRSF11A Antibody (9A725) - BSA Free [NB100-56508] - An intracellular stain was performed on MG-63 cells with RANK/TNFRSF11A Antibody (9A725) NB100-56508 (blue) and a matched isotype control MAB002 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/RANK-TNFRSF11A-Antibody-9A725-BSA-Free-Flow-Cytometry-NB100-56508-img0011.jpg){kind=icon}
![Western Blot: WT1 Antibody (6F-H2) [NB110-60011] - Hypomethylation of the Intron 1 CpG island results in WT1 expression. RNA was isolated from K562 and U937 cells growing under atmospheric conditions (Normox) and from U937 cells growing in 1% O2 (Hypox) and was analyzed by RT-PCR using primers that span exon 5 of the WT1 mRNA. Ribosomal RNA 36B4 is used as a positive control, and molecular weight markers (MW) are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0119837), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Western-Blot-NB110-60011-img0007.jpg "Western Blot: WT1 Antibody (6F-H2) [NB110-60011] - Hypomethylation of the Intron 1 CpG island results in WT1 expression. RNA was isolated from K562 and U937 cells growing under atmospheric conditions (Normox) and from U937 cells growing in 1% O2 (Hypox) and was analyzed by RT-PCR using primers that span exon 5 of the WT1 mRNA. Ribosomal RNA 36B4 is used as a positive control, and molecular weight markers (MW) are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0119837), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: WT1 Antibody (6F-H2) [NB110-60011] - Staining of human kidney glomerulus tissue. Heat mediated antigen retrieval was performed by heating in citrate buffer (pH 6) at 95C for 20 minutes. Image from verified customer review.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Immunohistochemistry-Paraffin-NB110-60011-img0006.jpg)
![Western Blot: WT1 Antibody (6F-H2) [NB110-60011] - Whole cell protein from human K562, HEK293 and kidney tissue was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-WT1 in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Western-Blot-NB110-60011-img0005.jpg)
![Immunohistochemistry: WT1 Antibody (6F-H2) [NB110-60011] - Analysis of Wilms Tumor 1 in human renal cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Immunohistochemistry-NB110-60011-img0003.jpg)
![Simple Western: WT1 Antibody (6F-H2) [NB110-60011] - Lane view shows a specific band for WT1 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/WT1-Antibody-6F-H2-Simple-Western-NB110-60011-img0004.jpg)
![Western Blot: WT1 Antibody (6F-H2) - BSA Free [NB110-60011] - Hypomethylation of Intron 1 CpG island results in WT1 expression. (C) Cell lysates from K562, U937, & HL60 cells treated with CoCl2, 5-azacytidine, or untreated controls analyzed by WB using an antibody against WT1. Histone H3 used as a loading control. Size of molecular weight markers is in kDa. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0119837), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-60011_mouse-monoclonal-wt1-antibody-6f-h2-310202415304296.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0012.jpg "Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with TDP-43/TARDBP Antibody conjugated to Alexa Fluor 488 (NB110-55376AF488) at 10 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-TARDBP at 2 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0011.jpg)
![Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody [NB110-55376] - Analysis of FFPE human placenta using TDP-43 antibody at 1:250 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunohistochemistry-Paraffin-NB110-55376-img0010.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in HeLa WCE.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0004.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY TARDBP cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-TARDBP.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in MCF-7 cells with DyLight 488 (Green). Nuclei and alpha-tubulin were counterstained with DAPI (Blue) and DyLight 550 (Red).](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Analysis using the DyLight 550 conjugate of NB110-55376. Staining of Human iPS derived neurons, fixed in 4% formaldehyde solution. NB110-55376R was diluted 1:200. All antibodies were diluted in PBS/BSA 3% (w/v) ) Triton X-100 0,3 % (v/v). Images taken by an Arrayscan (Cellomics). Blue dots in TDP staining is Hoechst.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Subcellular distribution of TDP-43 and CWC22 in control DRG sensory neurons. TDP-43 was stained diffusely in the nucleus, excluding SMN foci in sensory neurons. Scale bar: 10 um. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.028225) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0013.jpg)
![Western Blot: Nbs1 Antibody (1D7) [NB100-221] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with NBS1 antibody (1D7) [NB100-221] diluted at 1:500. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody.](http://images.novusbio.com/fullsize/Nbs1-Antibody-1D7-Western-Blot-NB100-221-img0010.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Nbs1 Antibody (1D7) [NB100-221] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with NBS1 antibody (1D7) [NB100-221] diluted at 1:500. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody.")
![<b>Genetic Strategies Validation. </b>Western Blot: Nbs1 Antibody (1D7) [NB100-221] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with Nbs1 Antibody (1D7) [NB100-221] diluted at1:500. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody. Observed Molecular Weight at ~95 kDa.](http://images.novusbio.com/fullsize/Nbs1-Antibody-1D7-Western-Blot-NB100-221-img0005.jpg)
![Western Blot: Nbs1 Antibody (1D7) [NB100-221] - Sample (30 ug of whole cell lysate). A: HepG2. 7.5% SDS PAGE. Nbs1 Antibody (1D7) [NB100-221] diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody. Observed Molecular Weight at ~97 kDa.](http://images.novusbio.com/fullsize/Nbs1-Antibody-1D7-Western-Blot-NB100-221-img0008.jpg)
![Immunocytochemistry/ Immunofluorescence: Nbs1 Antibody (1D7) [NB100-221] - Nbs1 antibody [1D7] detects Nbs1 protein at nucleus by immunofluorescent analysis.Sample: A431 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: Nbs1 stained by Nbs1 antibody [1D7] (NB100-221) diluted at 1:500.Red: phalloidin, a cytoskeleton marker, diluted at 1:200.](http://images.novusbio.com/fullsize/nb100-221_mouse-monoclonal-nbs1-antibody-1d7-910202420104417.jpg)